Table III.
Mean Inhibitory Anti-FVIII Antibody Titers Following Repeated Administration of FVIII, FVIII–PI, or PEGylated FVIII–PI in Hemophilia a Mice via s.c. or i.v. Routes
| Formulation | Inhibitory titers via subcutaneous route | Inhibitory titers via intravenous route | ||
|---|---|---|---|---|
| n | Mean ± SEM | n | Mean ± SEM | |
| Free FVIII | 15 | 690 ± 78 | 8 | 675 ± 71 |
| FVIII–PI | 10 | 183 ± 57* | 8 | 385 ± 237*** |
| FVIII–PI/PEG | 8 | 298 ± 59** | 6 | 1,352 ± 229**** |
Results are expressed in Bethesda units. Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison test. Free FVIII and FVIII–PI data have been previously published (31)
*p<0.001 compared to free FVIII s.c.; **p<0.01 compared to free FVIII s.c.; ***p<0/05 compared to free FVIII i.v.; ****p<0.001 compared to both free FVIII and FVIII‐PI i.v.